New research from Monash University published in Addiction reveals a sharp increase in cannabis-related hospital admissions across Victoria over the past decade, raising concerns about cannabis-related psychosis and the growing burden on the state's healthcare system.
The FDA has granted 510(k) clearance to Motivista, a prescription digital therapeutic developed by Click Therapeutics for adults with negative symptoms of schizophrenia. The treatment is cleared as an adjunct to clinician-managed outpatient care, addressing symptoms that current medications targeting hallucinations and delusions do not effectively treat.
Otsuka Pharmaceutical presented new phase 3b clinical trial results for SIMTRIYO (centanafadine) at Psych Congress 2026, demonstrating consistent improvements across ADHD symptoms, anxiety, executive function, and emotional dysregulation in adults with ADHD and comorbid anxiety disorders.
Researchers have made two breakthrough advances in autism research: identifying convergent patterns among 1,200+ autism-risk genes in brain activity, and successfully implanting human brain organoids into engineered mice to create living models for testing treatments for autism and epilepsy.
A trauma clinic in Birmingham that opened in July is providing mental health services to asylum seekers dealing with trauma. The center offers therapeutic support to individuals like Azad, an Iranian asylum seeker, who are seeking refuge in the UK.
Researchers at the University of Warwick analyzed data from more than 1.9 million people across 23 studies and found that ADHD is associated with nearly double the odds of constipation, 58% higher odds of irritable bowel syndrome, and an almost 50% increase in overall gastrointestinal symptoms.
Researchers have mapped critical protein interactions associated with profound autism using lab-grown brain organoids. The study provides new insights into the molecular mechanisms underlying severe forms of autism spectrum disorder.
New Zealand's pharmaceutical regulator has approved two psychiatrists to prescribe pharmaceutical-grade MDMA to patients suffering from severe post-traumatic stress disorder, marking a significant shift in mental health treatment policy.
The high-profile murder trial of Lindsay Clancy has brought postpartum psychosis into the spotlight. Women who have experienced the condition and medical professionals are calling for more research and understanding of this difficult mental illness.
A large study of over 2,000 women found those who used estrogen-only hormone therapy later in life were less likely to develop dementia and showed fewer signs of Alzheimer's disease in their brains upon autopsy.
A randomized controlled trial in Germany found that dronabinol, a cannabis-derived THC medication, significantly decreased nightmares in patients with post-traumatic stress disorder in a double-blind study published in Nature Medicine.
Researchers found that mild inflammation during pregnancy led mouse offspring to develop persistent brain overactivity and autism-like behaviors, but remarkably, one dose of rapamycin reversed these symptoms in adult mice within hours.
An experimental drug called diranersen demonstrated the ability to lower levels of tau protein in the brain and slow cognitive decline in early Alzheimer's patients, offering a new treatment approach distinct from current therapies. Clinical trial data released July 14, 2026, showed the drug can reduce tau tangles, one of the hallmark proteins associated with Alzheimer's disease.
New research using brain imaging has revealed three distinct subtypes of ADHD, each associated with different underlying brain systems, co-occurring conditions, and learning challenges. The findings suggest that inattentive and hyperactive-impulsive symptom profiles follow separate neural pathways, potentially enabling more targeted treatment interventions.
New research published in The Lancet shows that accelerated continuous theta burst stimulation (a-cTBS), a non-invasive brain stimulation technique, improved social communication in autistic children at one-month follow-up after just five days of treatment.
The federal autism committee met for the first time since HHS Secretary Kennedy fired most scientific experts and replaced them with activists and advocates, focusing on 'profound autism.'
Research from Emory University and University of Iowa demonstrates that noninvasive transcranial magnetic stimulation (TMS) can calm the brain's fear center and significantly reduce PTSD symptoms, offering a non-surgical, non-medication treatment option.
